首页> 外文期刊>Daru Journal of pharmaceutical sciences. >Itraconazole nanosuspension for oral delivery: Formulation, characterization and in vitro comparison with marketed formulation
【24h】

Itraconazole nanosuspension for oral delivery: Formulation, characterization and in vitro comparison with marketed formulation

机译:口服伊曲康唑纳米混悬液:制剂,表征和与市售制剂的体外比较

获取原文
           

摘要

Background and the purpose of the studyItraconazole is a poorly water soluble drug which results in its insufficient bioavailability. The purpose of the present study was to formulate Itraconazole in a nanosuspension to increase the aqueous solubility and to improve its formulation related parameters, dissolution and hence oral bioavailability.MethodsItraconazole nanosuspension was prepared by pearl milling technique using zirconium oxide beads as a milling media, Poloxamer 407 as a stabilizer and glycerol as a wetting agent. Effects of various process parameters like, stirring time and the ratio of the beads were optimized by keeping drug:surfactant:milling media (1:3.0:50) as a constant initially and then optimized process parameters were used to optimize formulation parameters by 32 factorial designs. The optimized nanosuspension was lyophilized using mannitol (1:1 ratio) as a cryoprotectant. Nanosuspension was characterized by particle size and size distribution, drug content, scanning electron microscopy, differential scanning colorimetry and X-ray diffraction techniques.ResultsOptimized nanosuspension showed spherical shape with surface oriented surfactant molecules and a mean particle diameter of 294 nm. There was no significant change in crystalline nature after formulation and it was found to be chemically stable with high drug content.ConclusionThe in vitro dissolution profile of the optimized formulation compared to the pure drug and marketed formulation (Canditral Capsule) by using 0.1N Hydrochloric acid as release medium showed higher drug release.
机译:研究的背景和目的伊曲康唑是一种水溶性差的药物,导致其生物利用度不足。本研究的目的是在纳米悬浮液中配制伊曲康唑,以提高其水溶性并改善其制剂相关参数,溶解度和口服生物利用度。方法采用珠光磨技术,以氧化锆珠为研磨介质,泊洛沙姆制备伊曲康唑纳米悬液。 407为稳定剂,甘油为润湿剂。最初通过保持药物:表面活性剂:研磨介质(1:3.0:50)为常数来优化各种工艺参数(如搅拌时间和珠粒比例)的影响,然后使用优化的工艺参数通过32阶乘优化配方参数设计。使用甘露醇(1:1比例)作为冷冻保护剂冻干优化的纳米悬浮液。通过粒径,粒径分布,药物含量,扫描电镜,差示扫描比色法和X射线衍射技术对纳米悬浮液进行表征。结果优化后的纳米悬浮液呈球形,表面活性剂分子为表面取向,平均粒径为294 nm。配制后的结晶性质没有明显变化,并且发现化学性质稳定且药物含量高。结论通过使用0.1N盐酸,与纯药物和市售制剂(Canditral Capsule)相比,优化制剂的体外溶出曲线因为释放介质显示出更高的药物释放。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号